FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de peptides

GHK-Cu

Copper Peptide / GHK-Copper / Copper Tripeptide-1

Recovery & Repair

GHK-Cu (Copper Peptide, Glycyl-L-Histidyl-L-Lysine:Copper(II)) is a naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine that declines significantly with age. First identified by Dr. Loren Pickart in 1973 from human albumin, it functions as a potent wound healing, anti-inflammatory, and tissue remodeling signal with demonstrated effects on gene expression affecting over 4,000 human genes. It is researched both as an injectable peptide and as a topical cosmeceutical ingredient for skin rejuvenation, hair growth, and collagen synthesis.

Mécanisme d'action

Naturally occurring copper-binding tripeptide (Gly-His-Lys) complexed with copper(II). Activates tissue remodeling genes, promotes collagen synthesis, increases decorin and glycosaminoglycan production, and recruits stem cells to injury sites. Also suppresses TGF-beta to reduce scarring.

Protocoles de recherche

Pour des fins de recherche uniquement. Pas de conseil médical.

Topical: 1-2% concentration applied twice daily. Subcutaneous: 50-200mcg daily near target area. Research cycles of 4-8 weeks for injectable use. Topical use is ongoing.

Notes de recherche

Clinical Research Status

GHK-Cu has extensive in vitro and animal research spanning over 50 years, with numerous published studies on wound healing, skin remodeling, and gene expression modulation. Multiple topical formulations containing GHK-Cu are commercially available as cosmeceuticals, though injectable forms remain investigational. No FDA-approved drug product exists, but the compound has GRAS (Generally Recognized as Safe) status in topical applications.

Key Published Findings

Gene expression studies (Broad Institute Connectivity Map) demonstrate that GHK-Cu resets approximately 32% of human genes toward a pattern associated with younger tissue, including upregulation of collagen, decorin, and tissue inhibitors of metalloproteinases. Research shows it stimulates production of glycosaminoglycans, promotes angiogenesis, and recruits immune cells to wound sites. Published data confirm it increases fibroblast proliferation, collagen synthesis by up to 70%, and significantly accelerates wound contraction in animal models.

Safety Profile

GHK-Cu has an excellent safety profile in both topical and injectable applications, with no significant adverse effects reported in published literature. Plasma GHK levels in healthy young adults are approximately 200ng/mL, declining to ~80ng/mL by age 60, suggesting physiological familiarity. Topical concentrations of 1-4% are well-tolerated without irritation, and injectable doses used in research (1-5mg daily) have not produced notable adverse events.

Drug Interactions & Contraindications

Theoretical concern exists with Wilson's disease (copper storage disorder) or other conditions of copper overload, as the peptide delivers bioavailable copper. May interfere with copper chelation therapy (penicillamine, trientine). No significant drug interactions have been documented, though concurrent use with other copper supplements should be monitored.

Comparison to Related Compounds

Unlike synthetic growth factors (EGF, FGF) which target single pathways, GHK-Cu acts as a broad-spectrum tissue remodeling signal affecting thousands of genes simultaneously. Compared to retinoids for skin anti-aging, GHK-Cu produces collagen stimulation without the irritation, dryness, or photosensitivity. AHK-Cu (Alanyl-Histidyl-Lysine:Copper) is a related analog with similar but less-studied properties.

Community Observations

Injectable research protocols typically use 1-5mg subcutaneously daily or several times per week, often combined with BPC-157 or TB-500 for systemic tissue repair. Topical application (cream, serum) at 1-3% concentration is popular for facial rejuvenation, hair thinning, and scar reduction with visible results typically reported at 4-8 weeks. The peptide is notable for its dual utility as both an injectable research compound and a commercially available topical with legitimate cosmetic efficacy.

Moitié de vie

~30-60 minutes

Réconstitution

Bacteriostatic water (BAC) for injection; aqueous solution for topical

Conservation

Lyophilisé

Refrigerate 2-8C up to 24 months.

Réconstitué

Refrigerate 2-8C. Use within 21 days.

Statut légal aux États-Unis

Research chemical (injectable) / Cosmetic ingredient (topical)

Autres noms connus

Copper PeptideGHK-CopperCopper Tripeptide-1

Questions fréquentes

Qu'est-ce que GHK-Cu ?

GHK-Cu (Copper Peptide, Glycyl-L-Histidyl-L-Lysine:Copper(II)) is a naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine that declines significantly with age. First identified by Dr. Loren Pickart in 1973 from human albumin, it functions as a potent wound healing, anti-inflammatory, and tissue remodeling signal with demonstrated effects on gene expression affecting over 4,000 human genes. It is researched both as an injectable peptide and as a topical cosmeceutical ingredient for skin rejuvenation, hair growth, and collagen synthesis.

Comment agit GHK-Cu ?

Naturally occurring copper-binding tripeptide (Gly-His-Lys) complexed with copper(II). Activates tissue remodeling genes, promotes collagen synthesis, increases decorin and glycosaminoglycan production, and recruits stem cells to injury sites. Also suppresses TGF-beta to reduce scarring.

Quel est le statut réglementaire de GHK-Cu aux États-Unis ?

Research chemical (injectable) / Cosmetic ingredient (topical)

Quelle est la demi-vie de GHK-Cu ?

~30-60 minutes

Sous quels autres noms GHK-Cu est-il connu ?

Copper Peptide, GHK-Copper, Copper Tripeptide-1

Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.

Lire la déclaration complète